Antifungal treatment administered by species on infection day 3.

<p>*Other species includes: <i>C. kefyr</i> (nine isolates), <i>C. famata</i> (four isolates), <i>C. rugosa</i> (three isolates), <i>C. utilis</i> (two isolates) and one isolate each of <i>C. fennica</i>, <i>C. fermentati</i>, <i>C. lipolytica</i>, and <i>Torulopsis</i> spp.</p>†<p>multiple species include <i>C. parapsilosis+C. glabrata</i> (n = 30), <i>C. tropicalis+C. glabrata</i> (n = 21), <i>C. krusei+C. glabrata</i> (n = 8), <i>C. dubliniensis+C. glabrata</i> (n = 3), <i>C. lusitaniae+C. glabrata</i> (n = 4), other <i>Candida</i> spp.<i>+C. glabrata</i> (n = 3), unknown <i>Candida spp.+C. glabrata</i> (n = 3), <i>C. guilliermondii+C. glabrata</i> (n = 2), <i>C. parapsilosis+C. krusei</i> (n = 5), <i>C. lusitaniae+C. krusei</i> (n = 2), <i>C. tropicalis+C. dubliniensis</i> (n = 1), <i>C. tropicalis+C. guilliermondii</i> (n = 1), <i>C. tropicalis+C. krusei</i> (n = 4), other <i>Candida</i> spp.+<i>C.</i> guilliermondii (n = 1), unknown <i>Candida</i> spp.+C. <i>dubliensis</i> (n = 1), <i>C. glabrata+C. krusei+C. lusitaniae</i> (n = 1), <i>C. dubliniensis+C.glabrata+C.guilliermondii</i> (n = 1).</p>§<p>patients in this category were in a blinded clinical trial.</p>‡<p>Other combination therapies included lipid amphotericin B +5-fluorocytosine (n = 7), lipid amphotericin B+fluconazole (n = 10), amphotericin B deoxycholate+lipid amphotericin B (n = 1), amphotericin B deoxycholate+fluconazole (n = 2), echinocandins +5-fluorocytosine (n = 1), echinocandins+amphotericin B deoxycholate (n = 9), echinocandins+fluconazole (n = 1), echinocandins+itraconazole (n = 1), fluconazole+blinded (n = 1), fluconazole+voriconazole (n = 8).